New York, November 17, 2025 — Leads & Copy — LifeMD, Inc. (Nasdaq: LFMD), a virtual primary care provider, announced its financial results for the three and nine months ending September 30, 2025. Total revenue increased 13% year-over-year to $60.2 million, with adjusted EBITDA rising 20% to $5.1 million.
Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% to $2.9 million. The company paid off all outstanding debt during the quarter and fully divested its majority stake in WorkSimpli after the quarter ended.
LifeMD continued to diversify its clinical platform with new launches in women’s health, men’s health, and psychiatry.
LifeMD’s Chairman and CEO, Justin Schreiber, noted that the third quarter marked an important step forward. Despite challenges in the weight management market due to competition from low-price compounded GLP-1 providers, the business demonstrated strength, continuing to onboard new weight management patients. Schreiber anticipates rapid evolution in the GLP-1 market with product innovation and improved pricing, positioning LifeMD to capitalize on these trends and accelerate growth in 2026.
The company is also gaining traction in diversifying its platform, seeing strong early results in behavioral health, women’s health, men’s hormone therapy, and personalized compounded ED therapies. The RexMD business returned to growth, adding nearly 10,000 net new subscribers. LifeMD also achieved regulatory approval for its Pennsylvania-based 503-A compounding pharmacy, licensed in 14 states with plans to expand to all 50 states. This pharmacy will strengthen the company’s competitive position by expanding its ability to deliver personalized therapies, improving cost structure, and enhancing patient experience.
LifeMD’s Chief Financial Officer, Marc Benathen, said that the company has taken major steps to significantly strengthen its balance sheet and liquidity, including paying off all outstanding debt and divesting its majority interest in WorkSimpli after the quarter ended. He added that telehealth Adjusted EBITDA profitability is up 294% year-to-date.
For the fourth quarter of 2025, LifeMD projects revenue between $45 million and $46 million, with adjusted EBITDA in the range of $3 million to $4 million. For the full year 2025, revenue is projected between $192 million and $193 million, reflecting a 24% increase versus 2024, and adjusted EBITDA is projected between $13.5 million and $14.5 million, a 254% increase versus 2024.
Key performance metrics for the telehealth business include an 18% revenue increase to $47.3 million and a 30% adjusted EBITDA increase to $2.9 million for the third quarter. Active telehealth subscribers increased 14% to approximately 310,000 at quarter-end.
LifeMD will host a conference call today at 4:30 p.m. Eastern time to discuss the results. A live and archived webcast will be available in the Investors section of the company’s website.
LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions. The company uses a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care.
Investor Contact:
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact:
Jessica Friedeman, Chief Marketing and Product Officer
press@lifemd.com
Source: LifeMD, Inc.
